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David J. Moliterno,
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W. Douglas Weaver,
MD, FACC†
Marc E. Shelton,
MD, FACC‡hile we were preparing the American College of Cardiology (ACC)
statement regarding drug-eluting stents (DES) for the December 2006 U.S.
Food and Drug Administration (FDA) Circulatory Systems Devices Panel
eeting, it became evident that we had many gaps in our current knowledge of this new
echnology. There were no questions about the superiority of DES over bare-metal
tents (BMS) in terms of reducing angiographic restenosis. However, the long-term
afety of these devices is far less certain (1). A clear emerging theme from the
eliberations is that there is a critical need for a better mechanism to systematically
ollect, collate, and share postmarket real-world data.
Stent thrombosis is an uncommon yet gravely serious risk after BMS and DES
mplantation and has commanded the attention of every interventional cardiologist. The
isk of stent thrombosis attenuates relatively quickly following placement of BMS, but
his is not the case with DES (2). The potential magnitude of this problem was brought
o light by the publication of the BASKET-LATE study from Switzerland (3). The
ecent publication of several additional studies presented at the FDA hearing reinforces
he concern about late stent thrombosis (LST) in DES-treated patients and the need for
ongitudinal data (4).
Within 6 months of approval, DES were used in approximately 80% of percutaneous
evascularization procedures in the U.S. and BMS were relegated to large vessels, which
ave a low rate of restenosis with any type of percutaneous revascularization (5). Bare-
etal stents also remain a first choice in those cases needing a short course of dual
ntiplatelet therapy, such as those with a planned near-term surgery or a history of
leeding (6).
Current real-world registries are inherently limited by a lack of valid control groups
nd often use historical controls. Efforts to compare LST among DES patients to data
rom older BMS registries have limited value, since the use of these stents is distinctly
ifferent from when they were first introduced. Most would agree that DES are
mplanted in patients with more comorbidities and complex lesions than would have
een attempted in the BMS era. It is also recognized that many of the DES randomized
rials performed for device approval had restricted enrollment criteria, making
xtrapolation of their findings to the greater population questionable. In addition,
andomized trials and short-duration registries sponsored by industry may raise a
oncern of bias, whether real or perceived.
The current published literature for stents is also challenging to collate because of
nconsistent criteria for enrollment, inconsistent definitions for acute stent thrombosis,
rom the *Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky; the
Henry Ford Heart and Vascular Institute, Detroit, Michigan; and the ‡Prairie Cardiovascular Consultants and Southern Illinois
niversity School of Medicine, Department of Medicine, Division of Cardiology, Springfield, Illinois. Dr. Moliterno has received
ast honoraria for serving on the Data and Safety Monitoring Boards of stent manufacturers including Boston Scientific and
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ompany.
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Postrelease informa-
tion on devices and
pharmaceuticals used
in contemporary
practice is an essen-
tial component of
quality patient care.ST and very late stent thrombosis (VLST), and clinical end points, and varied intervals
f follow-up after stent implantation. A research consortium has proposed standard
efinitions for definite, probable, and possible stent thrombosis (7). Bare-metal stents
emain a major advance in decreasing early angioplasty failures, and DES have an added
arget vessel revascularization (TVR) advantage, but the issue is the incidence of long-
erm complications (8).
The recent publication of the Bern-Rotterdam cohort experience suggests this higher
ate may steadily continue over time (9). Beyond limited data and a low event rate, it is
ikely that the etiology of LST is multifactorial. One certain factor is the discontinuation
f clopidogrel by many patients. Dual antiplatelet therapy has infrequently been
ontinued beyond 1 year (10). The optimal duration of dual therapy is unknown, and
hether dual therapy is protective from LST is uncertain (11). It is known that the risk
f stent thrombosis increases with premature discontinuation of dual antiplatelet therapy.
recent multisociety statement stressed the importance of 12 months of dual
ntiplatelet therapy after placement of a DES in patients at low risk for bleeding (12).
The risk of LST when stopping clopidogrel before surgery is unclear. Conversely, the
isk of bleeding associated with continuing dual therapy for noncardiac surgery is also
nknown. Many studies have identified potential patient characteristics such as disease
omorbidities, lesion types, platelet resistance, and compliance with therapy as
ndependent contributors to stent thrombosis. Stent design, delayed endothelialization,
nd deployment issues may be added contributors (13).
While it is useful to follow patients in postapproval, industry-sponsored registries, it
ould be of greater value to follow real-world application of pharmaceuticals and devices
n a much broader and larger population of patients. The Society for Thoracic Surgeons
STS) and the American College of Cardiology National Cardiovascular Data Registry
NCDR™) databases provide excellent platforms on which to build this capability and
urther our understanding of the role of intensive medical therapy, percutaneous
oronary intervention, and coronary artery bypass grafting. The NCDR™ data registries
ave more than 5 million patient records and add nearly 250,000 patients each quarter.
here are 3 million patients in the STS data registries. Currently, all Medicare patients
ho receive an implanted cardioverter-defibrillator (ICD) require entry in the NCDR’s
CD Registry™, and it is an option for non-Medicare patients. Since there is mandatory
eporting for Medicare patients, about 85% of all ICD implants are reported to this
egistry.
A strategy for longitudinal follow-up is under consideration to better define devices
sed, complications, and factors influencing clinical risk and benefit. This may help
mprove our current ability to treat those who have the most to gain and the least to
ose. A longitudinal database for other devices, procedures, and pharmaceuticals would
e invaluable.
What can the ACC do to help? A large-scale longitudinal NCDR™ database for
atients receiving coronary artery stents needs to be created and funded. This database
hould have open-entry to fully capture all U.S. procedures and have unique patient
dentifiers to protect confidentiality and facilitate the tracking of patients admitted to
ultiple institutions. Standardized definitions and systematic intervals of follow-up must
e created and agreed upon. Postrelease information on devices and pharmaceuticals
sed in contemporary practice is an essential component of quality patient care.
ppropriately, funding such a database is crucial and should not be an obstacle, provided
anufacturers are allowed to shift funding from otherwise required approval costs,
ostrelease surveillance, and registries. Such a database could:
Capture key elements of patient demographics and management at the point of entry
Identify specific devices and pharmaceuticals used
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The DES story
highlights the current
weaknesses in our
device surveillance
programs and the
pharmaceuticals that
are used in these
patients.Capture in-hospital complications and outcomes
Collate deaths from social security database or state-maintained records
Identify patient, hospital, and physician characteristics that contribute to outcomes
Confirm discharge status, management, and instructions
Follow ambulatory compliance with practice guidelines as well as patient compliance
Identify cohorts that benefit from specific therapies and those who do not
Follow both complications and freedom from events for devices and pharmaceuticals in
the general population
Avoid some limitations associated with small sample size registries that confound the
ability to identify infrequent complications
Quantify faster and more accurately low frequency adverse events
Reduce selection and reporting bias
Perhaps the next-generation stents with changes in stent design, polymers,
onpolymers (5), drug delivery, and new antiproliferatives will improve stent delivery
nd decrease stent thrombosis. Only when we are able to follow patients longitudinally
ill we be able to better understand the long-term effects of our new treatments. With
hese added data, physicians will be able to provide their patients with better and more
omplete information on short- and long-term risks and benefits. When a patient
resents with an acute coronary syndrome, the interventionalist will have better data on
hich to base management decisions. There needs to be a discussion with the patient
nd his or her family about the treatment choices including the lack of data and the
oncerns about LST. Informed consent is important for all patients and essential in the
ff-label use of DES.
The device manufacturers, pharmaceutical companies, and FDA need to support
ongitudinal data collection built on the foundation of the ACC/NCDR and STS
atabases to help identify those who will likely benefit the most or who are at risk for
arm from a particular procedure or pharmaceutical. A comprehensive database will help
etermine future recommendations and also uncover new problems. The DES story
ighlights the current weaknesses in our device surveillance programs and the
harmaceuticals that are used in these patients. We need to better understand the risks
nd effects of our new treatments.
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